April 1 (Reuters) - Maia Biotechnology Inc MAIA.A:
MAIA BIOTECHNOLOGY- PHASE 2 TRIAL THIO-101 EXPANSION UNDERWAY; POTENTIAL FILING IN 2026 FOR ACCELERATED APPROVAL
MAIA BIOTECHNOLOGY- PHASE 3 THIO-104 SET TO BEGIN IN MID-2025; POTENTIAL FILING IN 2026 FOR EARLY FULL APPROVAL
Source text: ID:nBw3b4svwa
Further company coverage: MAIA.A
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.